MeSH tree: D27.505.954.248.794.500
What if a new combination of cancer drugs could sound an alarm, alerting the body's immune system to invoke a targeted response to cancer cells? Findings from a new study appear in a paper published in Nucleic Acids Research.
Jun 11, 2026
0
6
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found ...
Apr 20, 2026
0
4
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
Apr 20, 2026
0
6
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented ...
Sep 6, 2025
0
25
